1. Academic Validation
  2. ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol

ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol

  • Blood. 2012 Aug 9;120(6):1262-73. doi: 10.1182/blood-2011-12-400184.
Emilia Mahoney 1 David M Lucas Sneha V Gupta Amy J Wagner Sarah E M Herman Lisa L Smith Yuh-Ying Yeh Leslie Andritsos Jeffrey A Jones Joseph M Flynn Kristie A Blum Xiaoli Zhang Amy Lehman Hui Kong Metin Gurcan Michael R Grever Amy J Johnson John C Byrd
Affiliations

Affiliation

  • 1 Division of Hematology, Department of Internal Medicine, College of Pharmacy, The Ohio State University (OSU), Columbus, OH 43210, USA.
Abstract

Cyclin dependent kinase (CDK) inhibitors, such as flavopiridol, demonstrate significant single-agent activity in chronic lymphocytic leukemia (CLL), but the mechanism of action in these nonproliferating cells is unclear. Here we demonstrate that CLL cells undergo Autophagy after treatment with therapeutic agents, including fludarabine, CAL-101, and flavopiridol as well as the endoplasmic reticulum (ER) stress-inducing agent thapsigargin. The addition of chloroquine or siRNA against Autophagy components enhanced the cytotoxic effects of flavopiridol and thapsigargin, but not the other agents. Similar to thapsigargin, flavopiridol robustly induces a distinct pattern of ER stress in CLL cells that contributes to cell death through IRE1-mediated activation of ASK1 and possibly downstream caspases. Both Autophagy and ER stress were documented in tumor cells from CLL patients receiving flavopiridol. Thus, CLL cells undergo Autophagy after multiple stimuli, including therapeutic agents, but only with ER stress mediators and CDK inhibitors is Autophagy a mechanism of resistance to cell death. These findings collectively demonstrate, for the first time, a novel mechanism of action (ER stress) and drug resistance (Autophagy) for CDK inhibitors, such as flavopiridol in CLL, and provide avenues for new therapeutic combination approaches in this disease.

Figures
Products